Extracorporeal photopheresis for the treatment of refractory Crohn's disease

Results of an open-label pilot study

Maria T Abreu, Christian von Tirpitz, Robert Hardi, Martin Kaatz, Gert Van Assche, Paul Rutgeerts, Emil Bisaccia, Sergi Goerdt, Stephen Hanauer, Robert Knobler, Peter Mannon, Lloyd Mayer, Thomas Ochsenkuhn, William J. Sandborn, Dennis Parenti, Kevin Lee, Walter Reinisch

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Extracorporeal photopheresis (ECP) is effective in immune-mediated disorders. A prospective, uncontrolled pilot study was conducted to evaluate the safety and efficacy of ECP in patients with active Crohn's disease (CD) who were refractory to or intolerant of immunosuppressants and/or anti-TNF therapies. Methods: Patients with moderate-to-severely active CD (Crohn's Disease Activity Index [CDAI] 220-450 points) underwent 12 weeks of ECP treatment (Weeks 1-4: twice weekly, every week; Weeks 5-12: twice weekly, every other week). Clinical response was defined as a decrease in the CDAI of ≥100 points or remission (CDAI <150 points) at Week 12. Patients who responded at Week 12 could receive an additional 12 weeks of ECP treatment (twice weekly, every other week) in an extension study. Results: Twenty-eight patients were enrolled with a mean baseline CDAI score of 314 (range 207-457). At Week 12, 14 patients (50%) responded; 13 patients responded within 6 weeks. Seven patients (25%) attained remission by Week 12. Three of 5 patients with open fistulae at baseline had fistula closure. Response was similar among patients naïve to anti-TNF agents and patients who had previously been refractory or intolerant to anti-TNF agents. Of the 12 patients who entered the extension study, 9 (75%) maintained their response at Week 24. Conclusions: In patients with moderate-to-severely active CD who were refractory to or intolerant of immunosuppressants and/or anti-TNF agents, ECP was well tolerated and induced clinical response (50%) and remission (25%) in patients. Most patients were able to maintain a response with continued treatments.

Original languageEnglish
Pages (from-to)829-836
Number of pages8
JournalInflammatory Bowel Diseases
Volume15
Issue number6
DOIs
StatePublished - Jul 16 2009

Fingerprint

Photopheresis
Crohn Disease
Therapeutics
Immunosuppressive Agents
Fistula
Immune System Diseases
Proxy

Keywords

  • 8-methoxypsoralen
  • Anti-TNF therapy
  • Crohn's disease
  • Extracorporeal photopheresis
  • Immunomodulators

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Extracorporeal photopheresis for the treatment of refractory Crohn's disease : Results of an open-label pilot study. / Abreu, Maria T; von Tirpitz, Christian; Hardi, Robert; Kaatz, Martin; Van Assche, Gert; Rutgeerts, Paul; Bisaccia, Emil; Goerdt, Sergi; Hanauer, Stephen; Knobler, Robert; Mannon, Peter; Mayer, Lloyd; Ochsenkuhn, Thomas; Sandborn, William J.; Parenti, Dennis; Lee, Kevin; Reinisch, Walter.

In: Inflammatory Bowel Diseases, Vol. 15, No. 6, 16.07.2009, p. 829-836.

Research output: Contribution to journalArticle

Abreu, MT, von Tirpitz, C, Hardi, R, Kaatz, M, Van Assche, G, Rutgeerts, P, Bisaccia, E, Goerdt, S, Hanauer, S, Knobler, R, Mannon, P, Mayer, L, Ochsenkuhn, T, Sandborn, WJ, Parenti, D, Lee, K & Reinisch, W 2009, 'Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study', Inflammatory Bowel Diseases, vol. 15, no. 6, pp. 829-836. https://doi.org/10.1002/ibd.20833
Abreu, Maria T ; von Tirpitz, Christian ; Hardi, Robert ; Kaatz, Martin ; Van Assche, Gert ; Rutgeerts, Paul ; Bisaccia, Emil ; Goerdt, Sergi ; Hanauer, Stephen ; Knobler, Robert ; Mannon, Peter ; Mayer, Lloyd ; Ochsenkuhn, Thomas ; Sandborn, William J. ; Parenti, Dennis ; Lee, Kevin ; Reinisch, Walter. / Extracorporeal photopheresis for the treatment of refractory Crohn's disease : Results of an open-label pilot study. In: Inflammatory Bowel Diseases. 2009 ; Vol. 15, No. 6. pp. 829-836.
@article{68f17626a59d4fc3bc09415753922ca0,
title = "Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study",
abstract = "Background: Extracorporeal photopheresis (ECP) is effective in immune-mediated disorders. A prospective, uncontrolled pilot study was conducted to evaluate the safety and efficacy of ECP in patients with active Crohn's disease (CD) who were refractory to or intolerant of immunosuppressants and/or anti-TNF therapies. Methods: Patients with moderate-to-severely active CD (Crohn's Disease Activity Index [CDAI] 220-450 points) underwent 12 weeks of ECP treatment (Weeks 1-4: twice weekly, every week; Weeks 5-12: twice weekly, every other week). Clinical response was defined as a decrease in the CDAI of ≥100 points or remission (CDAI <150 points) at Week 12. Patients who responded at Week 12 could receive an additional 12 weeks of ECP treatment (twice weekly, every other week) in an extension study. Results: Twenty-eight patients were enrolled with a mean baseline CDAI score of 314 (range 207-457). At Week 12, 14 patients (50{\%}) responded; 13 patients responded within 6 weeks. Seven patients (25{\%}) attained remission by Week 12. Three of 5 patients with open fistulae at baseline had fistula closure. Response was similar among patients na{\"i}ve to anti-TNF agents and patients who had previously been refractory or intolerant to anti-TNF agents. Of the 12 patients who entered the extension study, 9 (75{\%}) maintained their response at Week 24. Conclusions: In patients with moderate-to-severely active CD who were refractory to or intolerant of immunosuppressants and/or anti-TNF agents, ECP was well tolerated and induced clinical response (50{\%}) and remission (25{\%}) in patients. Most patients were able to maintain a response with continued treatments.",
keywords = "8-methoxypsoralen, Anti-TNF therapy, Crohn's disease, Extracorporeal photopheresis, Immunomodulators",
author = "Abreu, {Maria T} and {von Tirpitz}, Christian and Robert Hardi and Martin Kaatz and {Van Assche}, Gert and Paul Rutgeerts and Emil Bisaccia and Sergi Goerdt and Stephen Hanauer and Robert Knobler and Peter Mannon and Lloyd Mayer and Thomas Ochsenkuhn and Sandborn, {William J.} and Dennis Parenti and Kevin Lee and Walter Reinisch",
year = "2009",
month = "7",
day = "16",
doi = "10.1002/ibd.20833",
language = "English",
volume = "15",
pages = "829--836",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Extracorporeal photopheresis for the treatment of refractory Crohn's disease

T2 - Results of an open-label pilot study

AU - Abreu, Maria T

AU - von Tirpitz, Christian

AU - Hardi, Robert

AU - Kaatz, Martin

AU - Van Assche, Gert

AU - Rutgeerts, Paul

AU - Bisaccia, Emil

AU - Goerdt, Sergi

AU - Hanauer, Stephen

AU - Knobler, Robert

AU - Mannon, Peter

AU - Mayer, Lloyd

AU - Ochsenkuhn, Thomas

AU - Sandborn, William J.

AU - Parenti, Dennis

AU - Lee, Kevin

AU - Reinisch, Walter

PY - 2009/7/16

Y1 - 2009/7/16

N2 - Background: Extracorporeal photopheresis (ECP) is effective in immune-mediated disorders. A prospective, uncontrolled pilot study was conducted to evaluate the safety and efficacy of ECP in patients with active Crohn's disease (CD) who were refractory to or intolerant of immunosuppressants and/or anti-TNF therapies. Methods: Patients with moderate-to-severely active CD (Crohn's Disease Activity Index [CDAI] 220-450 points) underwent 12 weeks of ECP treatment (Weeks 1-4: twice weekly, every week; Weeks 5-12: twice weekly, every other week). Clinical response was defined as a decrease in the CDAI of ≥100 points or remission (CDAI <150 points) at Week 12. Patients who responded at Week 12 could receive an additional 12 weeks of ECP treatment (twice weekly, every other week) in an extension study. Results: Twenty-eight patients were enrolled with a mean baseline CDAI score of 314 (range 207-457). At Week 12, 14 patients (50%) responded; 13 patients responded within 6 weeks. Seven patients (25%) attained remission by Week 12. Three of 5 patients with open fistulae at baseline had fistula closure. Response was similar among patients naïve to anti-TNF agents and patients who had previously been refractory or intolerant to anti-TNF agents. Of the 12 patients who entered the extension study, 9 (75%) maintained their response at Week 24. Conclusions: In patients with moderate-to-severely active CD who were refractory to or intolerant of immunosuppressants and/or anti-TNF agents, ECP was well tolerated and induced clinical response (50%) and remission (25%) in patients. Most patients were able to maintain a response with continued treatments.

AB - Background: Extracorporeal photopheresis (ECP) is effective in immune-mediated disorders. A prospective, uncontrolled pilot study was conducted to evaluate the safety and efficacy of ECP in patients with active Crohn's disease (CD) who were refractory to or intolerant of immunosuppressants and/or anti-TNF therapies. Methods: Patients with moderate-to-severely active CD (Crohn's Disease Activity Index [CDAI] 220-450 points) underwent 12 weeks of ECP treatment (Weeks 1-4: twice weekly, every week; Weeks 5-12: twice weekly, every other week). Clinical response was defined as a decrease in the CDAI of ≥100 points or remission (CDAI <150 points) at Week 12. Patients who responded at Week 12 could receive an additional 12 weeks of ECP treatment (twice weekly, every other week) in an extension study. Results: Twenty-eight patients were enrolled with a mean baseline CDAI score of 314 (range 207-457). At Week 12, 14 patients (50%) responded; 13 patients responded within 6 weeks. Seven patients (25%) attained remission by Week 12. Three of 5 patients with open fistulae at baseline had fistula closure. Response was similar among patients naïve to anti-TNF agents and patients who had previously been refractory or intolerant to anti-TNF agents. Of the 12 patients who entered the extension study, 9 (75%) maintained their response at Week 24. Conclusions: In patients with moderate-to-severely active CD who were refractory to or intolerant of immunosuppressants and/or anti-TNF agents, ECP was well tolerated and induced clinical response (50%) and remission (25%) in patients. Most patients were able to maintain a response with continued treatments.

KW - 8-methoxypsoralen

KW - Anti-TNF therapy

KW - Crohn's disease

KW - Extracorporeal photopheresis

KW - Immunomodulators

UR - http://www.scopus.com/inward/record.url?scp=65249129016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249129016&partnerID=8YFLogxK

U2 - 10.1002/ibd.20833

DO - 10.1002/ibd.20833

M3 - Article

VL - 15

SP - 829

EP - 836

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 6

ER -